Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA85496
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$937,713Funder
National Health and Medical Research Council (NHMRC)Principal Investigator
N/A
Research Location
AustraliaLead Research Institution
University of QueenslandResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Health PersonnelHospital personnelNurses and Nursing StaffPhysicians
Abstract
Covid-19 causes severe respiratory infection, leading to death in some. Health care workers are at high risk of infection. To protect health care workers we propose a clinical trial to reduce respiratory illnesses using a drug called OM85 that has been used safely in Europe for decades. We hypothesise that OM85 will protect health care workers from developing the most serious respiratory infections, saving lives and allowing them to safely treat patients.